Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 4/20 | 0.33 |
| ▸ | PYGM | P11217 | 4/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9990245 | 0.91 | PDE4D (0.34) | PDE4DHTR2BOPRK1LMNAPDE3A | |
| SCHEMBL2236994 | 0.84 | BRPF1 (0.43) | RIPK1PYGLPYGMBRD4 | |
| SCHEMBL1740686 | 0.84 | BRPF1 (0.43) | RIPK1PYGLPYGMBRD4 | |
| SCHEMBL2236989 | 0.84 | BRPF1 (0.43) | RIPK1PYGLPYGMBRD4 | |
| SCHEMBL9990618 | 0.80 | PYGL (0.33) | RIPK1PYGLPYGMP2RX7 | |
| SCHEMBL17312378 | 0.70 | — | — | |
| SCHEMBL17312376 | 0.70 | — | — | |
| SCHEMBL9990198 | 0.70 | P2RX7 (0.30) | PDE4DHTR2BPYGLPYGMP2RX7 | |
| SCHEMBL17312591 | 0.68 | — | — | |
| SCHEMBL17312593 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319396-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | MSD K.K. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319396-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | DGAT1, DGAT2, GRIN1 | PDE4D 2556/4885HTR2B 275/4885OPRK1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.